Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 12, 2014, Pages 2519-2529

  Madeddu, Clelia ^a   Gramignano, Giulia ^b   Floris, Carlo ^c   Murenu, Giuseppe ^d   Sollai, Giuseppe ^d   Macciò, Antonio ^d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b San Gavino Hospital   (Italy)

^c Casa Di Cura Nuova Di Decimomannu   (Italy)

^d Ospedale Oncologico A Businco   (Italy)

Author keywords

Adiposity; Interleukin 6; Leptin; Oestrogen dependent breast cancer; Oxidative stress

Indexed keywords

AUTACOID; ESTROGEN; ESTROGEN RECEPTOR; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; LEPTIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

AGED; BLOOD; BODY MASS; BREAST TUMOR; CANCER STAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PATHOLOGY; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

AGED; BODY MASS INDEX; BREAST NEOPLASMS; ESTROGENS; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LEPTIN; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OXIDATIVE STRESS; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911388272     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12413     Document Type: Article

References (46)

1. Macciò A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes Rev. 2009; 10: 660-70.
2. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94: 606-16.
3. Dizdar O, Alyamac E. Obesity: an endocrine tumor? Med Hypotheses. 2004; 63: 790-2.
4. Vona-davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14: 189-206.
5. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89: 2548-56.
6. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114: 1752-61.
7. Bermano G, Smyth E, Goua M, et al. Impaired expression of glutathione peroxidase-4 gene in peripheral blood mononuclear cells: a biomarker of increased breast cancer risk. Cancer Biomark. 2010; 7: 39-46.
8. Kedzierska M, Olas B, Wachowicz B, et al. The lipid peroxidation in breast cancer patients. Gen Physiol Biophys. 2010; 29: 208-10.
9. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010; 28: 4058-65.
10. Acharya A, Das I, Chandhok D, et al. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev. 2010; 3: 23-34.
11. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-95.
12. Khan S, Shukla S, Sinha S, et al. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev. 2013; 24: 503-13.
13. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569-78.
14. Macciò A, Madeddu C, Gramignano G, et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med. 2010; 88: 677-86.
15. Niu J, Jiang L, Guo W, et al. The association between leptin level and breast cancer: a meta-analysis. PLoS ONE. 2013; 8: e67349.
16. Wu MH, Chou YC, Chou WY, et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009; 100: 578-82.
17. Cust AE, Stocks T, Lukanova A, et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat. 2009; 113: 567-76.
18. Geisler J, Haynes B, Ekse D, et al. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Steroid Biochem Mol Biol. 2007; 104: 27-34.
19. Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004; 64: 5870-5.
20. Ruan H, Lodish HF. Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 2003; 14: 447-55.
21. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obesity Res. 2001; 9: 414-7.
22. Purohit A, Ghilchik MW, Duncan L, et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab. 1995; 80: 3052-8.
23. Ghosh S, Ashcraft K. An IL-6 link between obesity and cancer. Front Biosci. 2013; 5: 461-78.
24. Sarvas JL, Khaper N, Lees SJ. The IL-6 paradox: context dependent interplay of SOCS3 and AMPK. J Diabetes Metab. 2013. doi: 10.4172/2155-6156.S13-003.
25. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer. 2001; 8: 197-209.
26. McTiernan A, Rajan KB, Tworoger SS, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003; 21: 1961-6.
27. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann NY Acad Sci. 2012; 1271: 37-43.
28. Grunt TW, Mariani GL. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 2013; 13: 188-204.
29. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev. 2011; 12: 1063-70.
30. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2630-7.
31. Crujeiras AB, Díaz-Lagares A, Carreira MC, et al. Oxidative stress associated to dysfunctional adipose tissue: a potential link between obesity, type 2 diabetes mellitus and breast cancer. Free Radic Res. 2013; 47: 243-56.
32. Loft S, Olsen A, Møller P, et al. Association between 8-oxo-7, 8-dihydro-2'-deoxyguanosine excretion and risk of postmenopausal breast cancer: nested case-control study. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1289-96.
33. Dai Q, Gao YT, Shu XO, et al. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. J Clin Oncol. 2009; 27: 2482-8.
34. Macciò A, Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. TheScientificWorldJournal. 2011; 11: 2020-36.
35. Basu S, Nachat-Kappes R, Caldefie-Chézet F, et al. Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations. Antioxid Redox Signal. 2013; 18: 323-60.
36. Cavalieri E, Frenkel K, Liehr JG, et al. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000; 27: 75-93.
37. Mobley JA, Brueggemeier RW. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis. 2004; 25: 3-9.
38. Sastre-Serra J, Valle A, Company MM, et al. Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med. 2010; 48: 506-12.
39. Esworthy RS, Baker MA, Chu FF. Expression of selenium-dependent glutathione peroxidase in human breast tumor cell lines. Cancer Res. 1995; 55: 957-62.
40. Dairkee SH, Nicolau M, Sayeed A, et al. Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. Oncogene. 2007; 26: 6269-79.
41. Liang X, Lu B, Scott GK, et al. Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol. 1998; 146: 151-61.
42. Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000; 92: 1926-34.
43. Karlsson E, Pérez-Tenorio G, Amin R, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res. 2013; 15: R96.
44. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012; 30: 2844-52.
45. Zhang X, Smith-Warner SA, Collins LC, et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 2012; 30: 3468-77.
46. Singh B, Bhat HK. Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancer. Carcinogenesis. 2012; 33: 2601-10.